Reason for request
Reassessment
Clinical Benefit
| Substantial |
Considering all these elements, the Committee deems that the clinical benefit of KYMRIAH 1.2 x 10^6 – 6 x 10^8 cells (tisagenlecleucel) dispersion for infusion remains substantial in “the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy” and at the MA dosages.
|
Clinical Added Value
| minor |
Considering:
- additional experience with respect to the real-world data for KYMRIAH (tisagenlecleucel) in the French DESCAR-T registry (26 activated centres, 388 treated patients, median follow-up of 15 months since eligibility), which are consistent with the clinical data (JULIET),
- the role of KYMRIAH (tisagenlecleucel) compared to YESCARTA (axicabtagene ciloleucel), which remains difficult to determine given the major methodological limitations of the indirect comparison provided,
- the safety profile marked by significant short-term toxicity,
- and the initial uncertainties identified, which persist despite the Transparency Committee’s requests, particularly with respect to:
- the exact effect size compared to historic management, in the absence of any robust comparison,
- maintenance of the clinical efficacy in the medium and long term, particularly concerning achievement of full recovery for patients in lasting remission,
- and the absence of medium and long-term safety data,
The Committee considers that its previous conclusions are not liable to be modified. On the basis of currently available data, the Committee deems that KYMRIAH 1.2 x 10^6 – 6 x 10^8 cells (tisagenlecleucel) dispersion for infusion provides a minor clinical added value (CAV IV) in terms of efficacy compared to the historic management of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy, based on various chemotherapies.
|
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
NCL9WRScg6UzHn1r